Dr. James Trevaskis

Dr. James Trevaskis has a basic science background in the molecular regulation of body weight and metabolic diseases. He has spent the last 17 years in the pharmaceutical industry serving as a project team leader and senior scientist at Amylin Pharmaceuticals, Novartis and AstraZeneca in roles focusing on developing novel treatments for obesity, diabetes and NASH. He led a team of ~30 research scientists at Gilead Sciences head of the Fibrosis Research Team where his teams nominated 3 clinical candidates into development. Currently he is an Associate Vice President in the Diabetes, Obesity and Complications early discovery research group at Eli Lilly & Company, based in Cambridge, MA, building and leading teams focusing on obesity, cardiovascular and renal disease.